Home » QuantRx Announces Phase I Clinical Trial for BFPET
QuantRx Announces Phase I Clinical Trial for BFPET
QuantRx Biomedical Corporation … announced that FluoroPharma, Inc., a company developing breakthrough cardiovascular molecular imaging agents for the PET market, is commencing Phase I clinical trials for BFPET following institutional review board (IRB) approval of the proposed studies.
Centre Daily Times
Centre Daily Times
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May